Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02986750
• Other study ID #: LT2258-PIV-0216
• Status: Completed
• Phase: Phase 4
• Start date: February 13, 2016
• Est. completion date: March 23, 2017

Study information

• Verified date: August 2019
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. However, exact information about influence on tear film thickness and corneal residence time of topical lubricants is still sparse, therefore no ideal treatment regimen has been found.

Recently a new method for assessment of tear film thickness based on ultra-high resolution optical coherence tomography (OCT) has become available. The aim of the present study is to assess the influence on tear film thickness of three different formulations of topical lubricants, in particular Thealoz Duo® Eye Drops, Optive® Eye Drops and Systane Ultra® Eye Drops in patients with moderate to severe dry eye disease. In addition, standard tests for dry eye syndrome, such as the ocular surface disease index (OSDI©), Schirmer I test, corneal fluorescein staining and determination of tear break up time (BUT) will be performed to compare the product effects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: March 23, 2017
• Est. primary completion date: March 23, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Men and women aged over 18 years

2. Signed and dated written informed consent

3. History of dry eye syndrome for at least 3 months

4. Tear Break Up Time (BUT) = 10 seconds or Schirmer I test = 5 mm and = 2mm

5. OSDI = 22

6. Normal ophthalmic findings except dry eye syndrome, ametropia < 6 Dpt.

7. No administration of topical lubricants 24 hours before the screening examination

Exclusion Criteria:

1. Presence of an ocular pathology judged by the investigator as incompatible with the study.

2. Any other clinical relevant ocular abnormality except DES.

3. History of allergy, known hypersensitivity to one of the components: the study medications or Fluorescein.

4. History of known clinically relevant allergy.

5. Medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplasic, haematological disease; severe psychiatric illness, etc.).

6. History of a recent acute illness with a recovery period within the 2 weeks before the inclusion visit (Day 0).

7. Pregnancy, lactation.

8. Pre-menopausal woman who is not using a reliable birth control method (oral contraceptives or coil) or is not surgically sterilised.

9. Participation in any high-speed or water-sports during the study without ocular protection (goggles or glasses).

10. Subject unable to understand the study instructions or unlikely to comply with the study schedule and treatment.

11. Participation in another clinical study in the 4 weeks before the start of the present study or at the same time as the present study.

12. Subject is a ward of court.

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Syndrome

Intervention

Device:
• Thealoz Duo Eye Drops
Manufacturer: Laboratoires Thea, France
• Optive Eye Drops
Manufacturer: Allergan Pharmaceuticals, Ireland
• Systane Ultra Eye Drops
Manufacturer: Alcon Pharma GmbH

Locations

Country	Name	City	State
Austria	Department of Clinical Pharmacology, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in tear film thickness as measured with Optical Coherence Tomography (OCT)	Tear film thickness as measured with Optical Coherence Tomography (OCT) predose and at defined time points after the first instillation, as well as on each study day	10 weeks; at baseline, 10 minutes, 20 minutes, 40 minutes, 60 minutes, 120 minutes and 240 minutes after instillation of eye drops as well as 4 weeks and 8 weeks after the first instillation
Secondary	Tear Break Up Time (BUT)		10 weeks
Secondary	Subjective evaluation of ocular comfort with questionnaire		10 weeks
Secondary	Schirmer I test		10 weeks
Secondary	OSDI score		10 weeks
Secondary	Corneal fluorescein staining (Oxford grading scale)		10 weeks
Secondary	Conjunctival hyperemia score		10 weeks
Secondary	Efficacy assessment of eye drops by the patient with questionnaire	Efficacy of eye drops will be performed by the patient by choosing one of the following options: Very satisfactory; Satisfactory; Not very satisfactory; Unsatisfactory	10 weeks
Secondary	Efficacy assessment of eye drops by the investigator with questionnaire	Efficacy of eye drops will be performed by the investigator by choosing one of the following options: Very satisfactory; Satisfactory; Not very satisfactory; Unsatisfactory	10 weeks